Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1172-1181

  Park, John W ^a   Hong, Keelung ^b   Kirpotin, Dmitri B ^b   Colbern, Gail ^b,d   Shalaby, Refaat ^b   Baselga, Jose ^c,e   Shao, Yvonne ^b   Nielsen, Ulrik B ^a   Marks, James D ^a   Moore, Dan ^b   Papahadjopoulos, Demetrios ^b   Benz, Christopher C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ALZA CORPORATION   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOLIPOSOME; MATRIGEL; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; GENE OVEREXPRESSION; GENE TARGETING; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RAT; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036554863     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Park, J. W., Hong, K., Kirpotin, D. B., Papahadjopoulos, D., and Benz, C. C. Immunoliposomes for cancer treatment. Adv. Pharmacol., 40: 399-435, 1997.
2. Lasic, D. D., and Papahadjopoulos, D. Liposomes revisited. Science (Wash. DC), 267: 1275-1276, 1995.
3. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
4. Huang, S. K., Mayhew, E. M., Gilani, S., Lasic, D. D., Martin, F. J., and Papahadjopoulos, D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res., 52: 6774-6781, 1992.
5. Horowitz, A. T., Barenholz, Y., and Gabizon, A. A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim. Biophys. Acta, 1109: 203-209, 1992.
6. Sznol, M., and Holmlund, J. Antigen-specific agents in development. Semin. Oncol., 24: 173-186, 1997.
7. Olayioye, M. A., Neve, R. M., Lane, H. A., and Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J., 19: 3159-3167, 2000.
8. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
9. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
10. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B. B., Henner, D., Wong, W. L. T., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.
11. HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14, 737-744, 1996.
12. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639-2648, 1999.
13. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
14. Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., Wood, W. I., Papahadjopoulos, D., and Benz, C. C. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA, 92: 1327-1331, 1995.
15. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W. L., Carter, P., Benz, C. C., and Papahadjopoulos, D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cell in vitro. Biochemistry, 36: 66-75, 1997.
16. Carter, P., Rodrigues, M. L., Park, J. W., and Zapata, G. Preparation and uses of Fab′ fragments from E. coli. In: J. McCafferty, H. R. Hoogenboom, and D. J. Chiswell (eds.), Antibody Engineering: A Practical Approach, pp. 291-308. Oxford: IRL Press, 1996.
17. Schier, R., Marks, J. D., Wolf, E. J., Apell, G., Wong, C., McCartney, J. E., Bookman, M. A., Huston, J. S., Houston, L. L., Weiner, L. M., et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology, 1: 73-81, 1995.
18. Haran, G., Cohen, R., Bar, L. K., and Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta, 1151: 201-215., 1993.
19. Lewis, G. D., Figari, I., Fendly, B., Wong, W. L., Carter, P., Gorman, C., and Shepard, H. M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother., 37: 255-263, 1993.
20. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1993.
21. Park, J. W., Stagg, R., Lewis, G. D., Carter, P., Maneval, D., Slamon, D. J., Jaffe, H., and Shepard, H. M. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. In: R. B. Dickson and M. E. Lippman (eds.), Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer, pp. 193-211. Boston: Kluwer Academic Publishers, 1992.
22. Park, J. W., Tripathy, D., Campbell, M., and Esserman, L. J. Biological therapy of breast cancer. Biodrugs, 14: 221-246, 2000.
23. Mass, R. D., Press, M., Anderson, S., Murphy, M., and Slamon, D. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization. Proc. Amer. Soc. Clin. Oncol., 20: 22a, 2001.
24. Vogel, C. L., Cobleigh, M., Tripathy, D., Mass, R., Murphy, M., and Stewart, S. J. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients. Proc. Am. Soc. Clin. Oncol., 20: 22a, 2001.
25. Baselga, J., Norton, L., Albanell, J., Kim, Y-M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
26. Heitjan, D. F. Generalized Norton-Simon models of tumour growth. Stat. Med., 10: 1075-1088, 1991.
27. Gabizon, A., Shiota, R., and Papahadjopoulos, D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. (Bethesda), 81: 1484-1488, 1989.
28. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., and Slamon, D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 18: 2241-2251, 1999.
29. Zalipsky, S., Hansen, C. B., Menezes, D. L. d., and Allen, T. M. Long-circulating, polyethylene glycol-grafted immunoliposomes. J. Controlled Release, 39: 153-161, 1996.
30. Goren, D., Horowitz. A. T., Zalipsky, S., Woodle, M. C., Yarden, Y., and Gabizon, A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer, 74: 1749-1756, 1996.
31. Neve, R. M., Nielsen, U. B., Kirpotin, D. B., Poul, M-A., Marks, J. D., and Benz, C. C. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem. Biophys. Res. Commun., 280: 274-279, 2000.
32. Huang, S. K., Lee, K. D., Hong, K., Friend, D. S., and Papahadjopoulos, D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res., 52: 5135-5143, 1992.
33. Ravdin, P. M. Should HER2 status be routinely measured for all breast cancer patients? Semin. Oncol., 26: 117-123, 1999.
34. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., and Henderson, I. C. c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
35. Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., Norton, L., and Liu, E. T. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. (Bethesda), 90: 1346-1360, 1998.
36. Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L., and Wolmark, N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. (Bethesda), 90: 1998.
37. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.